Post-seed extension · Healthtech

NovAccel raises approximately ¥290m in post-seed extension

XTech Fund 3, INOUE CORPORATION and individual investors backed the medical-isotope technology company.

NovAccel announced approximately ¥290 million in a post-seed extension on November 17. XTech Fund 3, INOUE CORPORATION and individual investors subscribed to new shares. The company is continuing its fundraising.

The capital will support RiSA, its compact superconducting accelerator for medical-isotope production, and development of actinium-225 manufacturing processes. NovAccel also plans to build sample-supply and quality-control capabilities and prepare for larger-scale production.

Use of funds

RiSA accelerator and Ac225 manufacturing process

Sample supply and quality control

Business development and scale-up preparation

Funding history

Post-seed extension · This round~¥290M

Sources

  1. NovAccel、ポストシードエクステンションラウンドで約2.9億円を調達 | 株式会社NovAccelのプレスリリースprtimes.jp · Nov 17, 2026